Another new ADC, sacituzumab govitecan (SG), shows a promise as a treatment strategy for BLCA by targeting trophoblast cell surface antigen 2 (Trop-2), with an ORR of 27% against metastatic bladder cancer (7). The gene discussed is TACSTD2; the disease is bladder transitional cell carcinoma.